[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518991":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":54,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Hubei Cancer Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CTV-omitted","EXPERIMENTAL","CTV was omitted for primary tumor radiotherapy for advanced NSCLC who responded to therapy with immunotherapy and chemotherapy.",[13],"Radiation: CTV omitted or delineated",{"label":15,"type":16,"description":17,"interventionNames":18},"CTV-delineated","ACTIVE_COMPARATOR","CTV was delineated for primary tumor radiotherapy for advanced NSCLC who responded to induction therapy with immunotherapy and chemotherapy.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","CTV omitted or delineated","Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Guang Han, PhD","Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":25,"email":35},"CONTACT","+86 13886048178","hg7913@hotmail.com",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Wuhan","Hubei","430079","China","CN",{"type":45,"coordinates":46},"Point",[47,48],114.26667,30.58333,{"lat":48,"lon":47},[51,53],{"name":52,"role":33,"phone":25,"phoneExt":25,"email":25},"Han Guang, MD",{"name":52,"role":30,"phone":25,"phoneExt":25,"email":25},{"type":30,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"HAN GUANG","Director of the department of Radiotherapy Oncology","100518991","primary-tumor-radiotherapy-omitting-ctv-for-patients-with-advanced-nsclc-responded-to-immunotherapy-and-chemotherapy-100518991",false,"NCT06037733","Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy","Primary Tumor Radiotherapy Omitting Clinical Target Volume for Patients With Advanced Non Small Cell Lung Cancer Responded to Immunotherapy and Chemotherapy","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC);\n2. After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend);\n3. Age 18 to 80 years old, performance status 0-1;\n4. measurable or evaluable lesions;\n5. Survival expectancy is not less than 6 months;\n6. adequate cardiac, pulmonary, renal, and hepatic and bone marrow function\n\nExclusion Criteria:\n\n1. tumor progress after therapy with immunotherapy and chemotherapy\n2. EGFR, ALK, or ROS1 mutation;\n3. Previous thoracic radiotherapy;\n4. grade 2 or more immune-related adverse events after induction immunotherapy\n5. Previous malignancies (except stage I non-melanic skin cancer or cervical carcinoma in situ);\n6. Pregnant or lactating women\n7. undergoing other clinical trials;\n8. Have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes;\n9. Patients with HIV positive and undergoing antiviral therapy;\n10. Active tuberculosis","ALL","18 Years","75 Years",{"count":68,"type":69},134,"ESTIMATED","INTERVENTIONAL",[72],"NA","The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy",[75,76,77],"Advanced Non-Small Cell Squamous Lung Cancer","Radiotherapy","Immunotherapy",[79],"omitting CTV","2024-03-13",{"date":82,"type":83},"2024-03-15","ACTUAL",{"date":80,"type":69},{"date":86,"type":69},"2027-10-08",{"name":5,"class":6},1]